Lake Street analyst Thomas Flaten lowered the firm’s price target on Aquestive Therapeutics (AQST) to $8 from $10 and keeps a Buy rating on the shares after the company reported Q4 revenues below the firm’s estimate and consensus. However, the focus on Aquestive “is (and, if not, should be)” Anaphylm and the NDA submission process is underway and will be completed this quarter, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Aquestive Therapeutics price target lowered to $4.75 from $5.50 at Alliance Global Partners
- Aquestive Therapeutics Reports 2024 Financial Results and Strategic Progress
- Aquestive Therapeutics: Strategic Advancements and Financial Strength Underpin Buy Rating
- Aquestive Therapeutics Initiates Anaphylm NDA Filing Process
- Aquestive Therapeutics sees FY25 revenue $47M-$56M , consensus $52.97M
Questions or Comments about the article? Write to editor@tipranks.com